La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
83 hedge funds and large institutions have $718M invested in La Jolla Pharmaceutical Company in 2017 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 46 increasing their positions, 15 reducing their positions, and 25 closing their positions.
207% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 15
122% more call options, than puts
Call options by funds: $11.7M | Put options by funds: $5.28M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
7% more capital invested
Capital invested by funds: $672M → $718M (+$46.1M)
14% less funds holding
Funds holding: 96 → 83 (-13)
40% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$24.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$23.7M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$17M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$14.7M |
| 5 |
BC
Broadfin Capital
New York
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$24.3M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$8.01M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$7.69M |
| 4 |
CLCM
Crawford Lake Capital Management
Lakewood,
New Jersey
|
-$5.12M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.1M |
LJPC Hedge Fund Activity: Q2 2017 in Review
83 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q2 2017, worth a combined $718M — up 6.9% from $672M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of LJPC and 15 opened new positions — a net loss of 10 holders — while 15 trimmed existing stakes and 46 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $24.2M. The largest seller was Franklin Resources, exiting entirely with an estimated $24.3M sold.
- 83 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q2 2017, down from 96 in Q1 2017.
- Funds reported $718M of La Jolla Pharmaceutical Company stock for Q2 2017, up 6.9% quarter-over-quarter.
- 15 funds opened new La Jolla Pharmaceutical Company positions in Q2 2017 and 25 closed out, a net change of -10 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q2 2017 was Janus Henderson Group, an estimated $24.2M added.
- The largest La Jolla Pharmaceutical Company seller in Q2 2017 was Franklin Resources, an estimated $24.3M sold.
Based on aggregated 13F filings for Q2 2017.